MedTrace Logo

Antihypertensive Effect and Safety of Peptides Derived From Coldwater Shrimp

NCT01583582 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 74

Last updated 2013-01-31

No results posted yet for this study

Summary

The purpose of this proof of concept study is to find out the efficacy of Marealis Refined Peptide Concentrate (RPC) from Coldwater Shrimp (Pandalus borealis) containing ACE-inhibiting peptides on blood pressure in subjects with mild or moderate hypertension.

Conditions

Interventions

DIETARY_SUPPLEMENT

Marealis Refined Peptide Concentrate

1200 mg per os, once a day, 8 weeks

DIETARY_SUPPLEMENT

Marealis Refined Peptide Concentrate

600 mg per os, twice a day, 8 weeks

DIETARY_SUPPLEMENT

Marealis Refined Peptide Concentrate

0 mg per os, daily, 8 weeks

Sponsors & Collaborators

  • Marealis AS

    lead INDUSTRY

Principal Investigators

  • Essi S Sarkkinen, Ph.D · Oy Foodfiles Ltd

  • Sakari A Nieminen, MD · Oy Foodfiles Ltd

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
30 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-03-31
Primary Completion
2012-12-31
Completion
2012-12-31

Countries

  • Finland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01583582 on ClinicalTrials.gov